On February 13, 2024, the Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma
Starpharma's Dep Irinotecan combination cancer drug has shown to be superior to Onivyde
Ipsen purchased Onivyde from Cambridge, Massachusetts-based Merrimack Pharmaceuticals in 2017 with an upfront payment of $575 million, plus US$450 million in potential milestones based on label expansions
